Drug news
Xeomin (incobotulinumtoxinA) filed with FDA for treatment of upper limb spasticity- Merz
Merz Neurosciences, a division of Merz North America, has submitted an sBLA to the FDA to seek approval for the use of Xeomin (incobotulinumtoxinA) in the treatment of upper limb spasticity. In addition, data from the open-label extension of its pivotal Phase III clinical trial in upper limb spasticity will be presented during the Annual Assembly of the American Academy of Physical Medicine & Rehabilitation.
Xeomin is already approved to treat cervical dystonia and abnormal spasm of the eyelids (blepharospasm).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins